ULBI vs. HALO
ULBI (Ultralife Corporation) and HALO (Halozyme Therapeutics, Inc.) are both stocks. ULBI operates in Electrical Equipment & Parts (Industrials), while HALO operates in Biotechnology (Healthcare). Over the past 10 years, ULBI returned 4.85%/yr vs 21.91%/yr for HALO. At a 0.14 correlation, their price movements are largely independent.
Performance
ULBI vs. HALO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ULBI achieves a 20.72% return, which is significantly higher than HALO's 3.74% return. Over the past 10 years, ULBI has underperformed HALO with an annualized return of 4.85%, while HALO has yielded a comparatively higher 21.91% annualized return.
ULBI
- 1D
- -2.88%
- 1M
- 4.31%
- YTD
- 20.72%
- 6M
- 22.21%
- 1Y
- -4.76%
- 3Y*
- 14.67%
- 5Y*
- -5.76%
- 10Y*
- 4.85%
HALO
- 1D
- 5.34%
- 1M
- 8.13%
- YTD
- 3.74%
- 6M
- 7.98%
- 1Y
- 30.97%
- 3Y*
- 27.65%
- 5Y*
- 12.08%
- 10Y*
- 21.91%
ULBI vs. HALO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ULBI Ultralife Corporation | 20.72% | -23.22% | 9.24% | 76.68% | -36.09% | -6.65% | -12.45% | 9.48% | 3.05% | 32.32% |
HALO Halozyme Therapeutics, Inc. | 3.74% | 40.77% | 29.36% | -35.04% | 41.51% | -5.85% | 140.89% | 21.19% | -27.79% | 105.06% |
Correlation
The correlation between ULBI and HALO is 0.10, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.10 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.12 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.13 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.13 |
Correlation (All Time) Calculated using the full available price history since Mar 17, 2004 | 0.14 |
Fundamentals
ULBI:
$115.02M
HALO:
$8.58B
ULBI:
-$0.49
HALO:
$2.87
ULBI:
0.61
HALO:
5.64
ULBI:
0.89
HALO:
39.06
ULBI:
$187.86M
HALO:
$1.51B
ULBI:
$43.39M
HALO:
$1.23B
ULBI:
$6.73M
HALO:
$980.05M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ULBI vs. HALO — Risk / Return Rank
ULBI
HALO
ULBI vs. HALO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ultralife Corporation (ULBI) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ULBI | HALO | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.08 | 1.04 | -1.12 |
Sortino ratioReturn per unit of downside risk | 0.30 | 1.55 | -1.25 |
Omega ratioGain probability vs. loss probability | 1.04 | 1.19 | -0.15 |
Calmar ratioReturn relative to maximum drawdown | -0.11 | 1.29 | -1.40 |
Martin ratioReturn relative to average drawdown | -0.17 | 2.47 | -2.65 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ULBI | HALO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.08 | 1.04 | -1.12 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.10 | 0.31 | -0.41 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.09 | 0.51 | -0.42 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.03 | 0.23 | -0.26 |
Drawdowns
ULBI vs. HALO - Drawdown Comparison
The maximum ULBI drawdown since its inception was -92.90%, which is greater than HALO's maximum drawdown of -74.26%. Use the drawdown chart below to compare losses from any high point for ULBI and HALO.
Loading charts...
Drawdown Indicators
| ULBI | HALO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.90% | -74.26% | -18.64% |
Max Drawdown (1Y)Largest decline over 1 year | -44.69% | -24.13% | -20.56% |
Max Drawdown (3Y)Largest decline over 3 years | -68.83% | -33.92% | -34.91% |
Max Drawdown (5Y)Largest decline over 5 years | -68.83% | -49.06% | -19.77% |
Max Drawdown (10Y)Largest decline over 10 years | -68.83% | -49.06% | -19.77% |
Current DrawdownCurrent decline from peak | -71.82% | -14.05% | -57.77% |
Average DrawdownAverage peak-to-trough decline | -63.48% | -31.91% | -31.57% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 27.26% | 12.55% | +14.71% |
Volatility
ULBI vs. HALO - Volatility Comparison
Ultralife Corporation (ULBI) has a higher volatility of 25.54% compared to Halozyme Therapeutics, Inc. (HALO) at 11.55%. This indicates that ULBI's price experiences larger fluctuations and is considered to be riskier than HALO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ULBI | HALO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 25.54% | 11.55% | +13.99% |
Volatility (6M)Calculated over the trailing 6-month period | 41.68% | 24.29% | +17.39% |
Volatility (1Y)Calculated over the trailing 1-year period | 58.55% | 30.34% | +28.21% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 59.02% | 39.53% | +19.49% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 55.19% | 42.91% | +12.28% |
Dividends
ULBI vs. HALO - Dividend Comparison
Neither ULBI nor HALO has paid dividends to shareholders.
Financials
ULBI vs. HALO - Financials Comparison
This section allows you to compare key financial metrics between Ultralife Corporation and Halozyme Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ULBI vs. HALO - Profitability Comparison
ULBI - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Ultralife Corporation reported a gross profit of 10.11M and revenue of 47.45M. Therefore, the gross margin over that period was 21.3%.
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a gross profit of 297.47M and revenue of 376.71M. Therefore, the gross margin over that period was 79.0%.
ULBI - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Ultralife Corporation reported an operating income of -215.00K and revenue of 47.45M, resulting in an operating margin of -0.5%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported an operating income of 184.52M and revenue of 376.71M, resulting in an operating margin of 49.0%.
ULBI - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Ultralife Corporation reported a net income of -451.00K and revenue of 47.45M, resulting in a net margin of -1.0%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a net income of 150.05M and revenue of 376.71M, resulting in a net margin of 39.8%.
Frequently Asked Questions
ULBI and HALO have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ULBI has higher volatility (25.54%) compared to HALO (11.55%). In terms of maximum drawdown, ULBI dropped -92.90% vs HALO's -74.26%.
HALO currently has the higher Sharpe Ratio (1.04 vs -0.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ULBI and HALO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer